Oxford University Innovation and Serum Institute partnered to develop R78C, a next-generation malaria vaccine candidate targeting blood-stage antigens.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Oxford & Serum Institute Team Up for Next-Gen Malaria Vaccine
R78C Vaccine candidate
Oxford University Innovation Partner institution
Serum Institute (World'S Largest By Volume) Manufacturer partner
RIPR And CyRPA Blood-Stage Antigens Target antigens